Oral acyclovir in the treatment of acute herpes zoster ophthalmicus
Autor: | Anthony C. Segreti, Daniel B. Jones, Jonathan H. Lass, Gary N. Foulks, D. H. King, John E. Sutphin, Kirk R. Wilhelmus, T. Liesegang, L. M. Cobo, Sharon Chapman |
---|---|
Rok vydání: | 1986 |
Předmět: |
Male
medicine.medical_specialty viruses medicine.medical_treatment Acyclovir Administration Oral Pain Keratitis medicine Humans Aciclovir Skin Chemotherapy business.industry Incidence (epidemiology) virus diseases Middle Aged medicine.disease Dermatology Surgery Ophthalmology Ophthalmic zoster Herpes Zoster Ophthalmicus Acute Disease Neuralgia Female business Uveitis medicine.drug |
Zdroj: | Ophthalmology. 93(6) |
ISSN: | 0161-6420 |
Popis: | Seventy-one nonimmunocompromised patients with herpes zoster ophthalmicus, presenting within seven days of onset of characteristic skin eruption, were enrolled in a prospective, longitudinal, randomized, double-masked, placebo-controlled trial with oral acyclovir. In a previous interim report we noted more prompt resolution of dermatomal signs and symptoms with acyclovir treatment. There was also a reduction of viral shedding in acyclovir-treated patients coupled with a trend to greater rate of microdissemination of the virus in placebo-treated patients (Cobo LM, et al. Ophthalmology 1985; 92:1574-83). While further substantiating these findings, we report that a ten-day course of treatment with oral acyclovir (600 mg, five times a day) is well-tolerated and significantly reduces the incidence and severity of the most common complications of herpes zoster ophthalmicus: dendritiform keratopathy, stromal keratitis, and uveitis. While this acyclovir treatment regimen reduces the zoster-related pain during the acute phase of the disease, especially in patients treated within 72 hours of onset of skin lesions, it has no evident effect on either incidence, severity, or duration of post-herpetic neuralgia in the patients studied. |
Databáze: | OpenAIRE |
Externí odkaz: |